Now 129+ heading higher. I expect they will split this in the near future 2-1 or 3-1. jmo
Unfortunately. It was a good board without him (General S) around. and now every comment is meant with a rebuttal. He knows all and sees all - 24/7 - Sad. Unlike Yahoo, you cannot delete or ignore a user as far as I know. Because of him, I only have about 10 messages showing on YMB.
I have and I never have to read his posts here. You play right into his little game when you respond and he knows he is getting under your skin which is obvious. Unfortunately ihub does not have an ignore feature.
sammy - any stock that has had a move like ARYC will retrace and take a breath before continuing up. Most will drop back 40-50% of the move, which was from .20 to .60 so the low .40's is on target. Also the lower Bollinger band is sitting at .38 which indicates oversold and we have touched it during the day, but not closed there. I think you will be rewarded handsomely. jmo
You need significant news to trigger a squeeze as these don't materialize out of thin air. There has to be a reason/catalyst for a huge spike in buying activity to panic the shorts into covering before the pps gets beyond their control. Usually this comes in the form of an approval, i.e., FDA, or a major partnership, and in many cases a buyout bid which was unexpected. A major partnership would be the only thing I see on the horizon. jmo
Without news, there is simply no reason for shorts to cover. As a stock treads water, the shorts strategy is to attack with bashing and misinformation which creates doubt and fear in the longs - which in turn makes them pull the trigger and sell. That is the game and it is therefore incumbent on the company to 'continually' produce news or have your pps suffer. jmo
OTC sucks - and if that same scenario was reversed to a 'buy' - the stock wouldn't even move a penny to the plus side. BTW - 110,000 shares is the average volume. What a game!!!
Mike - If I am not mistaken, we just shipped 100 genome tests to DHK/India for $100 each or $10K
To generate $160M we would have to sell 1.6M genome tests, and there are 314 million people just in the U.S. alone which means our penetration would be less than 1% per year at that level. Why wouldn't every doctor not want his/her patients to be tested at least once in their lifetime? I have also seen where they say it should be done once a year. These numbers seem ridiculously low to me if we are spreading this out in India and beyond. That 3 year contract with DHK of $16M is only 160,000 tests in a country with 1.5B people. Of course only those who can afford the test will get it - but still you are talking huge numbers. Insurance companies should be all over this as this could save them billions of dollars by covering a $100 test and getting a glimpse into a clients health future. No brainer. What am I missing here???
This is how manipulated the OTC is when last week 15,000 shares dropped the price 3.5¢ or 8%, while the 500K buy this morning lifts the pps 1¢. or 2.9%. Nice to see the buy though - as this is all to let buddies in at a low price. Lets hope this is in anticipation of an announcement - but I am not holding my breath. jmo/jd
Bio - that $5 price was all based on one product OvaDx - now they have five opportunities. I would love to see the price at $5 again. Company would have a market cap of only $150M. Pipeline of products, profitable, new funding onboard, and insiders buying on the open market. Love to see that float reduced.
it will be all over when they are on a talk show and the host asks . . . "how did you lose so much weight - you look fabulous!!!" HF's will have a hard time fighting that. It is only going to take one major personality to say Belviq was what I took, and we are getting closer to that happening. Oprah of course would be the ultimate poster child for this product. jmo
Well . . . I am hoping it is an announcement about a deal with a 'MAJOR' name. I see we just did a product/instrument deal with Google. Having one of these companies, Google or Facebook, being involved in the genome chip/card segment would be huge. This would be a big revenue maker for them and begins to move them away from relying on ad revenue - interesting to see how this will play out. Assuming this announcement about the Schena's buyback is intended to predate any big deal to grab shares around the .40¢ range before they escalate. jmo/jd
When everyone of the 'big boys' have loaded up - then they will announce news. We have only traded 13% of the average daily volume today - 22K shares so far.
Nice tweets but nothing to stir buying as we tread water here. Saw the 23andMe television commercial on mike&mike's ESPN morning show today - extremely well done and you can see Google's influence in the graphics and visuals. $99 DNA test kit.
Are not Illumina and Genentech in our microarray space, i.e., competitors??? Are we selling them the razor and they will reap the dollars from the sale of blades?
jda - what timeframes are you projecting these events, i.e., double top and then your $2 target price. Just curious - before end of year? 1Q 2014?